92 related articles for article (PubMed ID: 476673)
1. Enhancement of antitumor activity of 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine and Baker's antifol (triazinate) with carboxypeptidase G1.
Kalghatgi KK; Moroson BA; Horváth C; Bertino JR
Cancer Res; 1979 Sep; 39(9):3441-5. PubMed ID: 476673
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of DNA synthesis in normal and malignant human cells by triazinate (Baker's antifol) and methotrexate.
Skeel RT; Sawicki WL; Cashmore AR; Bertino JR
Cancer Res; 1976 Oct; 36(10):3659-64. PubMed ID: 953990
[TBL] [Abstract][Full Text] [Related]
3. Combination antifol therapy: observations on the development of resistant L1210 leukemic cells in vivo.
Browman GP; Lazarus H
Cancer Treat Rep; 1980; 64(2-3):231-6. PubMed ID: 7407755
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of a new triazine antifolate in mice, rats, dogs, and monkeys.
Cashmore AR; Skeel RT; Makulu DR; Gralla EJ; Bertino JR
Cancer Res; 1975 Jan; 35(1):17-22. PubMed ID: 803254
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of Baker's antifol (triazinate, TZT, NSC-139,105) in advanced squamous cell carcinoma of cervix.
Arseneau JC; Bundy B; Dolan T; Homesley H; DiSaia PJ
Am J Clin Oncol; 1982 Feb; 5(1):61-4. PubMed ID: 6211087
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the antitumor activity and toxicity of 2,4-diamino-5-(1-adamantyl)-6-methylpyrimidine and 2,4-diamino-5-(1-adamantyl)-6-ethylpyrimidine.
Zakrzewski SF; Dave C; Rosen F
J Natl Cancer Inst; 1978 May; 60(5):1029-33. PubMed ID: 580441
[TBL] [Abstract][Full Text] [Related]
7. Crystallographic studies of the antineoplastic antifolate 2,4-diamino-5-(3',4'-dichlorophenyl)-6-methylpyrimidine (DDMP) ethanesulfonate salt.
Cody V
Cancer Biochem Biophys; 1983; 6(3):173-7. PubMed ID: 6850552
[TBL] [Abstract][Full Text] [Related]
8. New dose-time relationships of folate antagonists to sustain inhibition of human lymphoblasts and leukemic cells in vitro.
Sedwick WD; Kutler M; Frazer T; Brown OE; Laszlo J
Cancer Res; 1979 Sep; 39(9):3612-8. PubMed ID: 314333
[TBL] [Abstract][Full Text] [Related]
9. Elevation of dihydrofolate reductase, thymidylate synthetase, and thymidine kinase in cultured mammalian cells after exposure to folate antagonists.
Chello PL; McQueen CA; DeAngelis LM; Bertino JR
Cancer Res; 1976 Jul; 36(7 PT 1):2442-9. PubMed ID: 1277151
[TBL] [Abstract][Full Text] [Related]
10. Human plasma and amino acids as moderators of uptake and metabolic consequences of antifolates in WIL-2 and human leukemia cells.
Fyfe MJ; Sedwick WD; Brown OE; Laszlo J
J Natl Cancer Inst; 1981 Mar; 66(3):445-51. PubMed ID: 6937701
[TBL] [Abstract][Full Text] [Related]
11. Experimental chemotherapy with 5-arylpyrimidine antifolates: Further studies on toxicity and the responsiveness of ascitic, solid, and intracranial sarcoma 180 to DDMP and DDMP with citrovorum factor.
Sirotnak FM; Moccio DM; Dorick DM
Cancer Treat Rep; 1977 Oct; 61(7):1325-32. PubMed ID: 303937
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a folate-cleaving enzyme, carboxypeptidase G 1 .
Chabner BA; Chello PL; Bertino JR
Cancer Res; 1972 Oct; 32(10):2114-9. PubMed ID: 5080761
[No Abstract] [Full Text] [Related]
13. Potentiation by clofibrate of in-vivo tumor inhibition by hydrazine sulfate and cytotoxic agents, in Walker 256 carcinosarcoma.
Gold J
Cancer Biochem Biophys; 1978; 3(1):41-5. PubMed ID: 552898
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of folate antagonists against methotrexate-resistant human leukemic lymphoblast CCRF-CEM cell lines.
Mini E; Moroson BA; Franco CT; Bertino JR
Cancer Res; 1985 Jan; 45(1):325-30. PubMed ID: 3855284
[TBL] [Abstract][Full Text] [Related]
15. Baker's antifol in combination with 5-fluorouracil and methyl-CCNU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group Study (Protocol 7764).
Shaw MT; Bonnet JD; Wilson H; Heilbrun LK
Cancer Treat Rep; 1980; 64(2-3):247-50. PubMed ID: 7407758
[TBL] [Abstract][Full Text] [Related]
16. Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics.
Abelson HT; Ensminger W; Rosowsky A; Uren J
Cancer Treat Rep; 1978 Oct; 62(10):1549-52. PubMed ID: 309355
[TBL] [Abstract][Full Text] [Related]
17. New approaches to chemotherapy with folate antagonists: use of leucovorin "rescue" and enzymic folate depletion.
Bertino JR; Levitt M; McCullough JL; Chabner B
Ann N Y Acad Sci; 1971 Nov; 186():486-95. PubMed ID: 4943812
[No Abstract] [Full Text] [Related]
18. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
19. Studies of Baker's antifol, methotrexate, and razoxane in advanced gastric cancer: A Gastrointestinal Tumor Study Group Report.
Bruckner HW; Lokich JJ; Stablein DM
Cancer Treat Rep; 1982 Sep; 66(9):1713-7. PubMed ID: 7116348
[TBL] [Abstract][Full Text] [Related]
20. Topical chemotherapy of intradermal Walker 256 carcinosarcoma with diaziquone and doxorubicin in the rat.
Moore DJ; Powis G; Richardson RL; Pittelkow MR
Cancer Res; 1985 Nov; 45(11 Pt 1):5466-72. PubMed ID: 4053022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
